AOD-9604 in Paso de Pirules — Fat Loss Peptide Research Guide
AOD-9604 research guide for Paso de Pirules. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Paso de Pirules: Sourcing, Purity & Protocols
For anyone in Paso de Pirules looking to source AOD-9604, the first thing to know is that this compound is available only through an online research supply market. This matters because AOD-9604 quality varies dramatically across the market — from verified research-grade material to material with significant impurity issues — and the vendor is the entire quality system. A credible AOD-9604 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. The sections below cover what Paso de Pirules researchers need to know about sourcing, verifying, and handling AOD-9604 for research purposes.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Paso de Pirules comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. Mass spectrometry in the COA establishes that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone cannot verify molecular identity. The combination of peer feedback and direct document verification is the most effective quality filter — community feedback surfaces recurring issues no single purchase reveals, and vice versa. For Paso de Pirules researchers making a first AOD-9604 purchase: work through this evaluation framework first, order conservatively at first, and confirm the COA batch number matches your received product before use.
Order AOD-9604 — ships to Paso de Pirules
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Reconstitute AOD-9604 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Quality AOD-9604 sourcing is inseparable from safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that proper COA verification addresses. For any individual considering AOD-9604 outside a formal research context: consult a qualified physician — this compound is not approved for human use and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
